This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Ottawa directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Modeling glioblastoma.
eLife · 2024 · first author
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
Molecular therapy : the journal of the American Society of Gene Therapy · 2023
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
Latest funding
- $738,225
A therapeutic strategy for PTEN tumour suppressor restoration in glioblastoma
CIHR · 2021 · Nominated PI
- $715,275
Targeted Covalent Inhibitors of Tissue Transglutaminase as Novel Anti-Cancer Therapeutics
CIHR · 2018 · Co-investigator
- $100,000
Oncolytic Virus Immunotherapy for Brain Cancer
CIHR · 2014 · Co-investigator
3 publications.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
Wong B, Bergeron A, Maznyi G, Ng K, Jirovec A, Birdi HK, Serrano D, Spinelli M, Thomson M, Taha Z, Alwithenani A, Chen A, Lorimer I, Vanderhyden B, Arulanandam R, Diallo JS
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA
A therapeutic strategy for PTEN tumour suppressor restoration in glioblastoma
Principal investigators: Lorimer, Ian Anthony J
Keywords: Biotherapeutics; Cell-Mediated Therapy; Glioblastoma; Pten
Targeted Covalent Inhibitors of Tissue Transglutaminase as Novel Anti-Cancer Therapeutics
Principal investigators: Keillor, Jeffrey W
Keywords: Cancer; Cancer Stem Cells; Chemoresistance; Drug Design; G-Protein; Medicinal Chemistry; Metastasis; Pharmacodynamics; Pharmacokinetics; Transglutaminase
Oncolytic Virus Immunotherapy for Brain Cancer
Principal investigators: Stojdl, David F
Keywords: Brain Cancer; Immunotherapy; Oncolytic Virus; Therapeutics
Evaluation of protein kinase C iota as a target for glioblastoma therapy
Principal investigators: Lorimer, Ian Anthony J
Keywords: Brain Tumours; Protein Kinase; Pten; Rna Interference; Tumour Initiating Cells; Tumour Xenografts
Stem Cell Network/Réseau de cellules souches
Principal investigators: Rudnicki, Michael
Evaluation of protein kinase C iota as a target for glioblastoma therapy
Principal investigators: Lorimer, Ian Anthony J
Keywords: Brain Tumours; Protein Kinase; Rna Interference; Tumour Xenografts
PKC iota and breast cancer.
Principal investigators: Paget, Judith A
Keywords: Atypical Protein Kinase; Breast Cancer; Cell Signalling; Pi3k-Akt Pathway; Pik3ca Mutations; Pkc Iota
Stem Cell Network/Réseau de cellules souches
Principal investigators: Rudnicki, Michael
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Jean-Simon Diallo and Barbara Vanderhyden: 3 shared papers
- Jean-Simon Diallo and Ian Lorimer: 1 shared paper
- Barbara Vanderhyden and Ian Lorimer: 1 shared paper
- Ian Lorimer and Ming-Sound Tsao: 1 shared paper
- Cancer Therapeutics
- Cellular and Molecular Medicine
- Biochemistry, Microbiology and Immunology
- Department of Laboratory Medicine and Pathobiology
Co-authors at University of Ottawa, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.